APO Research
Talk to an analyst

APO RESEARCH · REPORT

Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

Selected research

Market Analysis & Forecast

Global Capecitabine Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchCapecitabine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Capecitabine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Capecitabine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Capecitabine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Capecitabine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.

Read the full market overview

This report presents an overview of global market for Capecitabine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Capecitabine, also provides the sales of main regions and countries. Of the upcoming market potential for Capecitabine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Capecitabine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Capecitabine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Capecitabine sales, projected growth trends, production technology, application and end-user industry.

Capecitabine Segment by Company

Roche

Teva

Mylan

Hikma

Hengrui Medicine

Cipla

Reliance Group

Hetero

Capecitabine Segment by Type

500 mg

150 mg

Capecitabine Segment by Application

Breast Cancer

Colorectal Cancer

Stomach Cancer

Capecitabine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Capecitabine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Capecitabine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Capecitabine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Capecitabine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Capecitabine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Capecitabine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 500 mg Major Manufacturers Table 3. 150 mg Major Manufacturers Table 4. Global Capecitabine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Breast Cancer Major Manufacturers Table 6. Colorectal Cancer Major Manufacturers Table 7. Stomach Cancer Major Manufacturers Table 8. Capecitabine Industry Trends Table 9. Capecitabine Industry Drivers Table 10. Capecitabine Industry Opportunities and Challenges Table 11. Capecitabine Industry Restraints Table 12. Global Capecitabine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Capecitabine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Capecitabine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Capecitabine Revenue Market Share by Region (2021-2026) Table 16. Global Capecitabine Revenue Market Share by Region (2027-2032) Table 17. Global Capecitabine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Kg) Table 18. Global Capecitabine Sales by Region (2021-2026) & (Kg) Table 19. Global Capecitabine Sales by Region (2027-2032) & (Kg) Table 20. Global Capecitabine Sales Market Share by Region (2021-2026) Table 21. Global Capecitabine Sales Market Share by Region (2027-2032) Table 22. Global Capecitabine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Capecitabine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Capecitabine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Capecitabine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Capecitabine Sales Price (USD/g) of Manufacturers (2021-2026) Table 27. Global Capecitabine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Capecitabine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Capecitabine Manufacturers, Product Type & Application Table 30. Global Capecitabine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Capecitabine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Capecitabine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Capecitabine Revenue Market Share by Type (2021-2026) Table 37. Global Capecitabine Revenue Market Share by Type (2027-2032) Table 38. Global Capecitabine Sales by Type 2021 VS 2025 VS 2032 (Kg) Table 39. Global Capecitabine Sales by Type (2021-2026) & (Kg) Table 40. Global Capecitabine Sales by Type (2027-2032) & (Kg) Table 41. Global Capecitabine Sales Market Share by Type (2021-2026) Table 42. Global Capecitabine Sales Market Share by Type (2027-2032) Table 43. Global Capecitabine Price by Type (2021-2026) & (USD/g) Table 44. Global Capecitabine Price by Type (2027-2032) & (USD/g) Table 45. Global Capecitabine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Capecitabine Revenue Market Share by Application (2021-2026) Table 49. Global Capecitabine Revenue Market Share by Application (2027-2032) Table 50. Global Capecitabine Sales by Application 2021 VS 2025 VS 2032 (Kg) Table 51. Global Capecitabine Sales by Application (2021-2026) & (Kg) Table 52. Global Capecitabine Sales by Application (2027-2032) & (Kg) Table 53. Global Capecitabine Sales Market Share by Application (2021-2026) Table 54. Global Capecitabine Sales Market Share by Application (2027-2032) Table 55. Global Capecitabine Price by Application (2021-2026) & (USD/g) Table 56. Global Capecitabine Price by Application (2027-2032) & (USD/g) Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 60. Roche Capecitabine Product Portfolio Table 61. Roche Recent Development Table 62. Teva Company Information Table 63. Teva Business Overview Table 64. Teva Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 65. Teva Capecitabine Product Portfolio Table 66. Teva Recent Development Table 67. Mylan Company Information Table 68. Mylan Business Overview Table 69. Mylan Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 70. Mylan Capecitabine Product Portfolio Table 71. Mylan Recent Development Table 72. Hikma Company Information Table 73. Hikma Business Overview Table 74. Hikma Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 75. Hikma Capecitabine Product Portfolio Table 76. Hikma Recent Development Table 77. Hengrui Medicine Company Information Table 78. Hengrui Medicine Business Overview Table 79. Hengrui Medicine Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 80. Hengrui Medicine Capecitabine Product Portfolio Table 81. Hengrui Medicine Recent Development Table 82. Cipla Company Information Table 83. Cipla Business Overview Table 84. Cipla Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 85. Cipla Capecitabine Product Portfolio Table 86. Cipla Recent Development Table 87. Reliance Group Company Information Table 88. Reliance Group Business Overview Table 89. Reliance Group Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 90. Reliance Group Capecitabine Product Portfolio Table 91. Reliance Group Recent Development Table 92. Hetero Company Information Table 93. Hetero Business Overview Table 94. Hetero Capecitabine Sales (Kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 95. Hetero Capecitabine Product Portfolio Table 96. Hetero Recent Development Table 97. North America Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Capecitabine Sales by Type (2021-2026) & (Kg) Table 100. North America Capecitabine Sales by Type (2027-2032) & (Kg) Table 101. North America Capecitabine Sales Price by Type (2021-2026) & (USD/g) Table 102. North America Capecitabine Sales Price by Type (2027-2032) & (USD/g) Table 103. North America Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Capecitabine Sales by Application (2021-2026) & (Kg) Table 106. North America Capecitabine Sales by Application (2027-2032) & (Kg) Table 107. North America Capecitabine Sales Price by Application (2021-2026) & (USD/g) Table 108. North America Capecitabine Sales Price by Application (2027-2032) & (USD/g) Table 109. North America Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Capecitabine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 111. North America Capecitabine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 112. North America Capecitabine Sales by Country (2021 VS 2025 VS 2032) & (Kg) Table 113. North America Capecitabine Sales by Country (2021-2026) & (Kg) Table 114. North America Capecitabine Sales by Country (2027-2032) & (Kg) Table 115. North America Capecitabine Sales Price by Country (2021-2026) & (USD/g) Table 116. North America Capecitabine Sales Price by Country (2027-2032) & (USD/g) Table 117. United States Capecitabine Revenue (2021-2032) & (US$ Million) Table 118. Canada Capecitabine Revenue (2021-2032) & (US$ Million) Table 119. Mexico Capecitabine Revenue (2021-2032) & (US$ Million) Table 120. Europe Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Capecitabine Sales by Type (2021-2026) & (Kg) Table 123. Europe Capecitabine Sales by Type (2027-2032) & (Kg) Table 124. Europe Capecitabine Sales Price by Type (2021-2026) & (USD/g) Table 125. Europe Capecitabine Sales Price by Type (2027-2032) & (USD/g) Table 126. Europe Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Capecitabine Sales by Application (2021-2026) & (Kg) Table 129. Europe Capecitabine Sales by Application (2027-2032) & (Kg) Table 130. Europe Capecitabine Sales Price by Application (2021-2026) & (USD/g) Table 131. Europe Capecitabine Sales Price by Application (2027-2032) & (USD/g) Table 132. Europe Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Capecitabine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. Europe Capecitabine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. Europe Capecitabine Sales by Country (2021 VS 2025 VS 2032) & (Kg) Table 136. Europe Capecitabine Sales by Country (2021-2026) & (Kg) Table 137. Europe Capecitabine Sales by Country (2027-2032) & (Kg) Table 138. Europe Capecitabine Sales Price by Country (2021-2026) & (USD/g) Table 139. Europe Capecitabine Sales Price by Country (2027-2032) & (USD/g) Table 140. Germany Capecitabine Revenue (2021-2032) & (US$ Million) Table 141. France Capecitabine Revenue (2021-2032) & (US$ Million) Table 142. U.K. Capecitabine Revenue (2021-2032) & (US$ Million) Table 143. Italy Capecitabine Revenue (2021-2032) & (US$ Million) Table 144. Russia Capecitabine Revenue (2021-2032) & (US$ Million) Table 145. Spain Capecitabine Revenue (2021-2032) & (US$ Million) Table 146. Netherlands Capecitabine Revenue (2021-2032) & (US$ Million) Table 147. Switzerland Capecitabine Revenue (2021-2032) & (US$ Million) Table 148. Sweden Capecitabine Revenue (2021-2032) & (US$ Million) Table 149. Poland Capecitabine Revenue (2021-2032) & (US$ Million) Table 150. China Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 151. China Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 152. China Capecitabine Sales by Type (2021-2026) & (Kg) Table 153. China Capecitabine Sales by Type (2027-2032) & (Kg) Table 154. China Capecitabine Sales Price by Type (2021-2026) & (USD/g) Table 155. China Capecitabine Sales Price by Type (2027-2032) & (USD/g) Table 156. China Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 157. China Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 158. China Capecitabine Sales by Application (2021-2026) & (Kg) Table 159. China Capecitabine Sales by Application (2027-2032) & (Kg) Table 160. China Capecitabine Sales Price by Application (2021-2026) & (USD/g) Table 161. China Capecitabine Sales Price by Application (2027-2032) & (USD/g) Table 162. Asia Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 163. Asia Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 164. Asia Capecitabine Sales by Type (2021-2026) & (Kg) Table 165. Asia Capecitabine Sales by Type (2027-2032) & (Kg) Table 166. Asia Capecitabine Sales Price by Type (2021-2026) & (USD/g) Table 167. Asia Capecitabine Sales Price by Type (2027-2032) & (USD/g) Table 168. Asia Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 169. Asia Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 170. Asia Capecitabine Sales by Application (2021-2026) & (Kg) Table 171. Asia Capecitabine Sales by Application (2027-2032) & (Kg) Table 172. Asia Capecitabine Sales Price by Application (2021-2026) & (USD/g) Table 173. Asia Capecitabine Sales Price by Application (2027-2032) & (USD/g) Table 174. Asia Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Asia Capecitabine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 176. Asia Capecitabine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 177. Asia Capecitabine Sales by Country (2021 VS 2025 VS 2032) & (Kg) Table 178. Asia Capecitabine Sales by Country (2021-2026) & (Kg) Table 179. Asia Capecitabine Sales by Country (2027-2032) & (Kg) Table 180. Asia Capecitabine Sales Price by Country (2021-2026) & (USD/g) Table 181. Asia Capecitabine Sales Price by Country (2027-2032) & (USD/g) Table 182. Japan Capecitabine Revenue (2021-2032) & (US$ Million) Table 183. South Korea Capecitabine Revenue (2021-2032) & (US$ Million) Table 184. India Capecitabine Revenue (2021-2032) & (US$ Million) Table 185. Australia Capecitabine Revenue (2021-2032) & (US$ Million) Table 186. Taiwan Capecitabine Revenue (2021-2032) & (US$ Million) Table 187. Southeast Asia Capecitabine Revenue (2021-2032) & (US$ Million) Table 188. SAMEA Capecitabine Revenue by Type (2021-2026) & (US$ Million) Table 189. SAMEA Capecitabine Revenue by Type (2027-2032) & (US$ Million) Table 190. SAMEA Capecitabine Sales by Type (2021-2026) & (Kg) Table 191. SAMEA Capecitabine Sales by Type (2027-2032) & (Kg) Table 192. SAMEA Capecitabine Sales Price by Type (2021-2026) & (USD/g) Table 193. SAMEA Capecitabine Sales Price by Type (2027-2032) & (USD/g) Table 194. SAMEA Capecitabine Revenue by Application (2021-2026) & (US$ Million) Table 195. SAMEA Capecitabine Revenue by Application (2027-2032) & (US$ Million) Table 196. SAMEA Capecitabine Sales by Application (2021-2026) & (Kg) Table 197. SAMEA Capecitabine Sales by Application (2027-2032) & (Kg) Table 198. SAMEA Capecitabine Sales Price by Application (2021-2026) & (USD/g) Table 199. SAMEA Capecitabine Sales Price by Application (2027-2032) & (USD/g) Table 200. SAMEA Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. SAMEA Capecitabine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. SAMEA Capecitabine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. SAMEA Capecitabine Sales by Country (2021 VS 2025 VS 2032) & (Kg) Table 204. SAMEA Capecitabine Sales by Country (2021-2026) & (Kg) Table 205. SAMEA Capecitabine Sales by Country (2027-2032) & (Kg) Table 206. SAMEA Capecitabine Sales Price by Country (2021-2026) & (USD/g) Table 207. SAMEA Capecitabine Sales Price by Country (2027-2032) & (USD/g) Table 208. Brazil Capecitabine Revenue (2021-2032) & (US$ Million) Table 209. Argentina Capecitabine Revenue (2021-2032) & (US$ Million) Table 210. Chile Capecitabine Revenue (2021-2032) & (US$ Million) Table 211. Colombia Capecitabine Revenue (2021-2032) & (US$ Million) Table 212. Peru Capecitabine Revenue (2021-2032) & (US$ Million) Table 213. Saudi Arabia Capecitabine Revenue (2021-2032) & (US$ Million) Table 214. Israel Capecitabine Revenue (2021-2032) & (US$ Million) Table 215. UAE Capecitabine Revenue (2021-2032) & (US$ Million) Table 216. Turkey Capecitabine Revenue (2021-2032) & (US$ Million) Table 217. Iran Capecitabine Revenue (2021-2032) & (US$ Million) Table 218. Egypt Capecitabine Revenue (2021-2032) & (US$ Million) Table 219. Key Raw Materials Table 220. Raw Materials Key Suppliers Table 221. Capecitabine Distributors List Table 222. Capecitabine Customers List Table 223. Research Programs/Design for This Report Table 224. Authors List of This Report Table 225. Secondary Sources Table 226. Primary Sources List of Figures Figure 1. Capecitabine Image Figure 2. Global Capecitabine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Capecitabine Market Size Share 2021 VS 2025 VS 2032 Figure 4. 500 mg Image Figure 5. 150 mg Image Figure 6. Global Capecitabine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Capecitabine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Breast Cancer Image Figure 9. Colorectal Cancer Image Figure 10. Stomach Cancer Image Figure 11. Global Capecitabine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Capecitabine Revenue (2021-2032) & (US$ Million) Figure 13. Global Capecitabine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Capecitabine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Capecitabine Revenue Market Share by Region (2021-2032) Figure 16. Global Capecitabine Sales (2021-2032) & (Kg) Figure 17. Global Capecitabine Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 18. Global Capecitabine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Capecitabine Sales YoY (2021-2032) & (Kg) Figure 20. Europe Capecitabine Sales YoY (2021-2032) & (Kg) Figure 21. China Capecitabine Sales YoY (2021-2032) & (Kg) Figure 22. Asia (Excluding China) Capecitabine Sales YoY (2021-2032) & (Kg) Figure 23. South America, Middle East and Africa Capecitabine Sales YoY (2021-2032) & (Kg) Figure 24. Global Capecitabine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Capecitabine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Capecitabine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Capecitabine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Capecitabine Revenue Market Share by Type (2021-2032) Figure 30. Global Capecitabine Sales by Type (2021 VS 2025 VS 2032) & (Kg) Figure 31. Global Capecitabine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Capecitabine Sales Market Share by Type (2021-2032) Figure 33. Global Capecitabine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Capecitabine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Capecitabine Revenue Market Share by Application (2021-2032) Figure 36. Global Capecitabine Sales by Application (2021 VS 2025 VS 2032) & (Kg) Figure 37. Global Capecitabine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Capecitabine Sales Market Share by Application (2021-2032) Figure 39. North America Capecitabine Revenue Share by Type (2021-2032) Figure 40. North America Capecitabine Sales Share by Type (2021-2032) Figure 41. North America Capecitabine Revenue Share by Application (2021-2032) Figure 42. North America Capecitabine Sales Share by Application (2021-2032) Figure 43. North America Capecitabine Revenue Share by Country (2021-2032) Figure 44. North America Capecitabine Sales Share by Country (2021-2032) Figure 45. Europe Capecitabine Revenue Share by Type (2021-2032) Figure 46. Europe Capecitabine Sales Share by Type (2021-2032) Figure 47. Europe Capecitabine Revenue Share by Application (2021-2032) Figure 48. Europe Capecitabine Sales Share by Application (2021-2032) Figure 49. Europe Capecitabine Revenue Share by Country (2021-2032) Figure 50. Europe Capecitabine Sales Share by Country (2021-2032) Figure 51. China Capecitabine Revenue Share by Type (2021-2032) Figure 52. China Capecitabine Sales Share by Type (2021-2032) Figure 53. China Capecitabine Revenue Share by Application (2021-2032) Figure 54. China Capecitabine Sales Share by Application (2021-2032) Figure 55. Asia Capecitabine Revenue Share by Type (2021-2032) Figure 56. Asia Capecitabine Sales Share by Type (2021-2032) Figure 57. Asia Capecitabine Revenue Share by Application (2021-2032) Figure 58. Asia Capecitabine Sales Share by Application (2021-2032) Figure 59. Asia Capecitabine Revenue Share by Country (2021-2032) Figure 60. Asia Capecitabine Sales Share by Country (2021-2032) Figure 61. SAMEA Capecitabine Revenue Share by Type (2021-2032) Figure 62. SAMEA Capecitabine Sales Share by Type (2021-2032) Figure 63. SAMEA Capecitabine Revenue Share by Application (2021-2032) Figure 64. SAMEA Capecitabine Sales Share by Application (2021-2032) Figure 65. SAMEA Capecitabine Revenue Share by Country (2021-2032) Figure 66. SAMEA Capecitabine Sales Share by Country (2021-2032) Figure 67. Capecitabine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Capecitabine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 500 mg
  • 150 mg
Applications
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
Companies covered
  • Roche
  • Teva
  • Mylan
  • Hikma
  • Hengrui Medicine
  • Cipla
  • Reliance Group
  • Hetero

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Capecitabine Market by Type
  3. 1.2.1 Global Capecitabine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 500 mg
  5. 1.2.3 150 mg
  6. 1.3 Capecitabine Market by Application
  7. 1.3.1 Global Capecitabine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Breast Cancer
  9. 1.3.3 Colorectal Cancer
  10. 1.3.4 Stomach Cancer
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Capecitabine Market Dynamics
  1. 2.1 Capecitabine Industry Trends
  2. 2.2 Capecitabine Industry Drivers
  3. 2.3 Capecitabine Industry Opportunities and Challenges
  4. 2.4 Capecitabine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Capecitabine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Capecitabine Revenue by Region
  3. 3.2.1 Global Capecitabine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Capecitabine Revenue by Region (2021-2026)
  5. 3.2.3 Global Capecitabine Revenue by Region (2027-2032)
  6. 3.2.4 Global Capecitabine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Capecitabine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Capecitabine Sales by Region
  9. 3.4.1 Global Capecitabine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Capecitabine Sales by Region (2021-2026)
  11. 3.4.3 Global Capecitabine Sales by Region (2027-2032)
  12. 3.4.4 Global Capecitabine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Capecitabine Revenue by Manufacturers
  2. 4.1.1 Global Capecitabine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Capecitabine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Capecitabine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Capecitabine Sales by Manufacturers
  6. 4.2.1 Global Capecitabine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Capecitabine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Capecitabine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Capecitabine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Capecitabine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Capecitabine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Capecitabine Manufacturers, Product Type & Application
  13. 4.7 Global Capecitabine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Capecitabine Market CR5 and HHI
  16. 4.8.2 2025 Capecitabine Tier 1, Tier 2, and Tier 3
5 Capecitabine Market by Type
  1. 5.1 Global Capecitabine Revenue by Type
  2. 5.1.1 Global Capecitabine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Capecitabine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Capecitabine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Capecitabine Sales by Type
  6. 5.2.1 Global Capecitabine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Capecitabine Sales by Type (2021-2032) & (Kg)
  8. 5.2.3 Global Capecitabine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Capecitabine Price by Type
6 Capecitabine Market by Application
  1. 6.1 Global Capecitabine Revenue by Application
  2. 6.1.1 Global Capecitabine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Capecitabine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Capecitabine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Capecitabine Sales by Application
  6. 6.2.1 Global Capecitabine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Capecitabine Sales by Application (2021-2032) & (Kg)
  8. 6.2.3 Global Capecitabine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Capecitabine Price by Application
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Roche Capecitabine Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Teva Capecitabine Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Mylan
  14. 7.3.1 Mylan Company Information
  15. 7.3.2 Mylan Business Overview
  16. 7.3.3 Mylan Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Mylan Capecitabine Product Portfolio
  18. 7.3.5 Mylan Recent Developments
  19. 7.4 Hikma
  20. 7.4.1 Hikma Company Information
  21. 7.4.2 Hikma Business Overview
  22. 7.4.3 Hikma Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Hikma Capecitabine Product Portfolio
  24. 7.4.5 Hikma Recent Developments
  25. 7.5 Hengrui Medicine
  26. 7.5.1 Hengrui Medicine Company Information
  27. 7.5.2 Hengrui Medicine Business Overview
  28. 7.5.3 Hengrui Medicine Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hengrui Medicine Capecitabine Product Portfolio
  30. 7.5.5 Hengrui Medicine Recent Developments
  31. 7.6 Cipla
  32. 7.6.1 Cipla Company Information
  33. 7.6.2 Cipla Business Overview
  34. 7.6.3 Cipla Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cipla Capecitabine Product Portfolio
  36. 7.6.5 Cipla Recent Developments
  37. 7.7 Reliance Group
  38. 7.7.1 Reliance Group Company Information
  39. 7.7.2 Reliance Group Business Overview
  40. 7.7.3 Reliance Group Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Reliance Group Capecitabine Product Portfolio
  42. 7.7.5 Reliance Group Recent Developments
  43. 7.8 Hetero
  44. 7.8.1 Hetero Company Information
  45. 7.8.2 Hetero Business Overview
  46. 7.8.3 Hetero Capecitabine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hetero Capecitabine Product Portfolio
  48. 7.8.5 Hetero Recent Developments
8 North America
  1. 8.1 North America Capecitabine Market Size by Type
  2. 8.1.1 North America Capecitabine Revenue by Type (2021-2032)
  3. 8.1.2 North America Capecitabine Sales by Type (2021-2032)
  4. 8.1.3 North America Capecitabine Price by Type (2021-2032)
  5. 8.2 North America Capecitabine Market Size by Application
  6. 8.2.1 North America Capecitabine Revenue by Application (2021-2032)
  7. 8.2.2 North America Capecitabine Sales by Application (2021-2032)
  8. 8.2.3 North America Capecitabine Price by Application (2021-2032)
  9. 8.3 North America Capecitabine Market Size by Country
  10. 8.3.1 North America Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Capecitabine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Capecitabine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Capecitabine Market Size by Type
  2. 9.1.1 Europe Capecitabine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Capecitabine Sales by Type (2021-2032)
  4. 9.1.3 Europe Capecitabine Price by Type (2021-2032)
  5. 9.2 Europe Capecitabine Market Size by Application
  6. 9.2.1 Europe Capecitabine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Capecitabine Sales by Application (2021-2032)
  8. 9.2.3 Europe Capecitabine Price by Application (2021-2032)
  9. 9.3 Europe Capecitabine Market Size by Country
  10. 9.3.1 Europe Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Capecitabine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Capecitabine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Capecitabine Market Size by Type
  2. 10.1.1 China Capecitabine Revenue by Type (2021-2032)
  3. 10.1.2 China Capecitabine Sales by Type (2021-2032)
  4. 10.1.3 China Capecitabine Price by Type (2021-2032)
  5. 10.2 China Capecitabine Market Size by Application
  6. 10.2.1 China Capecitabine Revenue by Application (2021-2032)
  7. 10.2.2 China Capecitabine Sales by Application (2021-2032)
  8. 10.2.3 China Capecitabine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Capecitabine Market Size by Type
  2. 11.1.1 Asia Capecitabine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Capecitabine Sales by Type (2021-2032)
  4. 11.1.3 Asia Capecitabine Price by Type (2021-2032)
  5. 11.2 Asia Capecitabine Market Size by Application
  6. 11.2.1 Asia Capecitabine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Capecitabine Sales by Application (2021-2032)
  8. 11.2.3 Asia Capecitabine Price by Application (2021-2032)
  9. 11.3 Asia Capecitabine Market Size by Country
  10. 11.3.1 Asia Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Capecitabine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Capecitabine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Capecitabine Market Size by Type
  2. 12.1.1 SAMEA Capecitabine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Capecitabine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Capecitabine Price by Type (2021-2032)
  5. 12.2 SAMEA Capecitabine Market Size by Application
  6. 12.2.1 SAMEA Capecitabine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Capecitabine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Capecitabine Price by Application (2021-2032)
  9. 12.3 SAMEA Capecitabine Market Size by Country
  10. 12.3.1 SAMEA Capecitabine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Capecitabine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Capecitabine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Capecitabine Value Chain Analysis
  2. 13.1.1 Capecitabine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Capecitabine Production Mode & Process
  6. 13.2 Capecitabine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Capecitabine Distributors
  9. 13.2.3 Capecitabine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst